Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial Meeting Abstract


Authors: Feldman, D. R.; Lee, C. H.; Molina, A. M.; Knezevic, A.; Chen, Y.; Chaim, J.; Coskey, D. T.; Ged, Y.; Tickoo, S.; Reuter, V. E.; Patil, S.; Xiao, H.; Aghalar, J.; Apollo, A. J.; Carlo, M. I.; Motzer, R. J.; Voss, M. H.
Abstract Title: Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial
Meeting Title: 2018 Genitourinary Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 6 Suppl.
Meeting Dates: 2018 Feb 8-10
Meeting Location: San Francisco, CA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-02-20
Language: English
DOI: 10.1200/JCO.2018.36.6_suppl.627
PROVIDER: manual
Notes: Meeting Abstract: 627
Altmetric Score
MSK Authors
  1. Sujata Patil
    373 Patil
  2. Joshua Chaim
    17 Chaim
  3. Robert Motzer
    718 Motzer
  4. Han Xiao
    22 Xiao
  5. Satish K Tickoo
    368 Tickoo
  6. Darren Richard Feldman
    167 Feldman
  7. Martin Henner Voss
    123 Voss
  8. Yingbei Chen
    220 Chen
  9. Ana Maria Luisa Molina
    43 Molina
  10. Victor Reuter
    892 Reuter
  11. Arlyn Apollo
    3 Apollo
  12. Maria Isabel Carlo
    21 Carlo
  13. Chung-Han   Lee
    34 Lee
  14. Devyn Taylor Coskey
    9 Coskey
  15. Yasser Mohamed Ali Ged
    2 Ged